BioAge Labs Inc. Stock Price, News & Analysis

BioArctic (Nasdaq Stockholm: BIOA) announced on October 14, 2025 that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease, was selected by TIME as one of the Best Inventions of 2025 in the Medical and Healthcare category.

The selection recognizes the product's innovation and potential impact. Leqembi was developed in collaboration with Eisai, which leads clinical development, regulatory approvals and global commercialization. BioArctic retains rights to commercialize Leqembi in the Nordic region together with Eisai. Prescribing information in the US includes a Boxed WARNING.

BioArctic (NASDAQ: BIOA) partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October 6, 2025 as a maintenance option for early Alzheimer’s disease (MCI or mild dementia) after an initial 18-month IV induction.

After 18 months of 10 mg/kg IV every two weeks, patients may continue IV every four weeks or switch to a weekly 360 mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education, financial/insurance support, an injection tracker and an app. Full prescribing information and a boxed warning apply.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of 10 mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing.

Leqembi, initially approved in China in January 2024, is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that Australia's Therapeutic Goods Administration (TGA) has approved Leqembi (lecanemab) for treating early Alzheimer's disease. The approval specifically targets adult patients with mild cognitive impairment or mild dementia who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.

This approval follows a review process initiated in March 2025 after an initial rejection in February 2025. Leqembi, developed through collaboration between BioArctic and Eisai, originated from Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease. While Eisai leads global commercialization, BioArctic maintains Nordic region commercialization rights in partnership with Eisai.

BioAge Labs (NASDAQ:BIOA) has initiated a Phase 1 clinical study of BGE-102, a novel brain-penetrant NLRP3 inhibitor developed in collaboration with HitGen (SSE:688222). The drug candidate, discovered using HitGen's DNA-encoded library (DEL) technology platform, is being developed initially for obesity treatment.

BGE-102 is an orally available small molecule that targets NLRP3, a key driver of age-related inflammation implicated in neurodegenerative conditions, cardiovascular disease, and metabolic disorders. The clinical trial initiation triggers an undisclosed milestone payment to HitGen under their collaboration agreement.

The partnership, which began with successful hit identification in April 2021, has resulted in joint patent filings and a published research paper in February 2024. Both companies continue to collaborate on additional drug discovery programs using HitGen's DEL platform, which contains over 1.2 trillion small molecules.

BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.

Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.

BioArctic AB (Nasdaq Stockholm: BIOA-B) announced that its two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, plan to sell a minor portion of their shareholdings in the company. The company disclosed this information in compliance with EU Market Abuse Regulation requirements.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has initiated a rolling submission of a Supplemental Biologics License Application (sBLA) to the FDA for Leqembi Iqlik's subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease treatment. This follows the recent approval of Leqembi Iqlik for maintenance dosing in the US on August 29, 2025.

If approved, Leqembi Iqlik would become the first anti-amyloid treatment offering at-home injection from start to maintenance. The proposed dosing regimen includes 500 mg SC dosing (two 250 mg injections) weekly, as an alternative to bi-weekly intravenous dosing. The autoinjector requires only 15 seconds per injection and could potentially reduce healthcare resources associated with IV administration.

Leqembi, currently approved in 48 countries and under review in 10 others, uniquely targets both amyloid plaque and protofibrils in Alzheimer's disease treatment.

BioArctic AB (Nasdaq Stockholm: BIOA-B) announced that its partner Eisai received FDA approval for LEQEMBI IQKLIK™, a subcutaneous autoinjector version of lecanemab for maintenance treatment of early Alzheimer's disease. The new formulation will launch on October 6, 2025.

After 18 months of initial Leqembi intravenous treatment, patients can either continue with IV infusions every four weeks or switch to the new weekly 360 mg subcutaneous injection. Leqembi uniquely targets both amyloid plaque and protofibrils, potentially impacting tau accumulation. The treatment aims to slow disease progression and maintain therapeutic benefits through continuous maintenance therapy.